Chapter 1

Additional Controlled Substances

Section 1.  Purpose. The purpose of these rules is to add, delete, and reschedule controlled substances in the Wyoming Controlled Substances Act of 1971. Some changes will be made to similarly control a substance in response to the publication of a final order in the Federal Register designating that substance as a controlled substance under federal law. Other changes will be made at the discretion of the Wyoming Attorney General, in his or her capacity as the Commissioner of Drugs and Substances Control, with the advice of the Advisory Board on Drugs and Substances Control.

Section 2.  Authority.  The Commissioner of Drugs and Substances Control's  rulemaking authority is found at Wyoming Statute § 35-7-1011(a) and (d), which allow the Commissioner to add, delete, and reschedule substances to the control schedules pursuant to the procedures of the Wyoming Administrative Procedure Act.

Section 3.  Additional Controlled Substances. The Commissioner of Drugs and Substances Control adds the following substances to Schedule II:

(a) Synthetic cannabinoids:

 (i) Syndros-drug product consisting of Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta -9- THC) oral solution.

(b) Opioids:

 (i) Thiafentanil, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers; and

 (ii) Oliceridine (N-[(3-methoxythiophen-2-yl)methyl] ({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro [4.5]decan-9-yl]ethyl})amine), including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible.

(c) Immediate precursors:

 (i) Immediate precursors to fentanyl:

  (A) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl); and

  (B) 4-anilino-N-phenethylpiperidine (ANPP).

Section 4. Substances Excluded From Control.  The Commissioner of Drugs and Substances Control excludes the following substances and their salts from Schedule II:

(a) Opium and opiate derivatives:

 (i) Naldemedine;

 (ii) Naloxegol;

 (iii) 6β-Naltrexol; and

 (iv) Samidorphan.

(b) Coca leaf and ecgonine derivatives:

 (i) [123I]ioflupane; and

 (ii) [18F]FP-CIT.